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Abstract The type I interferon receptor (IFNAR1) is composed
of two transmembrane polypeptides, IFNAR-1 and IFNAR-2.
Human IFNAR-1 has low intrinsic affinity for IFNs, but
enhances the affinity for IFNs of the complex over that of
HuIFNAR-2 alone, and modulates the ligand specificity. Bovine
cells respond to human alpha interferons. The bovine homologue
of HuIFNAR-1, BoIFNAR-1, when expressed in heterologous
cells, confers high-affinity binding and broad specificity for
human type I IFNs. A soluble fusion protein of the ectodomain of
BoIFNAR-1 and an immunoglobulin Fc domain was produced. In
contrast to HuIFNAR-1, this protein competes strongly with
human cells for IFN binding, and directly binds a wide spectrum
of human type I IFNs, including diverse IFN-Ks, IFN-L and IFN-
g, with moderate to high affinity. This accounts for much of the
specificity for human IFNs possessed by bovine cells, with several
exceptions. The BoIFNAR-1 ectodomain, in contrast to HuIF-
NAR-1, may be useful for studies of binary and ternary
complexes with IFNs and IFNAR-2, and for purification, assay
and biological neutralization protocols.
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1. Introduction
The type I interferon receptor (IFNAR) is believed to be a
heterodimer of two transmembrane polypeptides, IFNAR-1
and IFNAR-2 [2^6]. The complex binds all type I IFNs:
IFN-Ks, IFN-L, IFN-g, and, in ruminants, IFN-d [7^10]. In
human cells, IFNAR-2 has moderate to high a⁄nity for di-
verse IFNs [3,11^16]. HuIFNAR-1 has low intrinsic a⁄nity
for IFNs ([2,17^19]; Langer, unpublished data), but contrib-
utes to ligand binding by increasing the a⁄nity and modulat-
ing the speci¢city from that which is seen with IFNAR-2
alone [3,12^16,20,21]. Both subunits are required for high-af-
¢nity ligand binding and physiological responses (reviewed in
[5,6]).
Bovine cells are highly sensitive to human IFN-Ks and have
often been used in the study of human IFN-Ks [10,22^24].
Curiously, a single protein from bovine MDBK cells or tis-
sues, but not from human Daudi cells, was su⁄cient for bind-
ing radiolabeled human IFN-K2 [25,26]. The broad ligand
speci¢city of bovine cells motivated the cloning of bovine
IFNAR-1 (BoIFNAR-1) [27,28], which has about 68% amino
acid identity with human IFNAR-1 (HuIFNAR-1).
Data from experiments where BoIFNAR-1 is expressed on
heterologous cells is consistent with BoIFNAR-1 having a
major role in the broad speci¢city of bovine cells for
HuIFN-Ks. Thus, human cells transfected with BoIFNAR-1
have a bovine-like speci¢city, characterized by a greatly en-
hanced response to HuIFN-K1 (= IFN-KD), which has low
binding a⁄nity for, and activity on human cells [27]. Simi-
larly, BoIFNAR-1 transiently expressed on COS cells or Xe-
nopus laevis oocytes e⁄ciently promoted the binding of
HuIFN-K2 and IFN-K8 [17,28]. In contrast, under similar
conditions HuIFNs bind weakly to HuIFNAR-1. Weak bind-
ing and covalent crosslinking of IFN was demonstrated to
HuIFNAR-1 expressed on Xenopus oocytes [17], and a weak
a⁄nity of about 1037 M was estimated for the interaction of
the soluble ectodomain of HuIFNAR-1 with a £uorescent
derivative of IFN-K8 [18].
It is a reasonable to hypothesize that a small number of
amino acids in the ectodomain of human and bovine IFNAR-
1 determine the respectively weak and strong binding of hu-
man type I IFNs. Although cellular IFNAR-1 is part of a
functional receptor complex with IFNAR-2, the study of lig-
and interactions with isolated subunits has been a productive
approach with other heteromeric cytokine receptors, such as
those for IL-2 and TNF, and it would be desirable to recon-
stitute the ternary complex of IFN with IFNAR-1 and IF-
NAR-2. Human IFNAR-1 is a particular challenge because of
its weak interaction with ligands, so that a study of human
IFN interactions with BoIFNAR-1 may be quite useful in
identifying critical regions or amino acids in IFNAR-1/IFN
interactions, and in studying the stoichiometry and structure
of the ternary complex.
As a ¢rst step, we produced the BoIFNAR-1 extracellular
domain (‘ectodomain’) as a soluble fusion protein (‘immu-
noadhesin’) with the human immunoglobulin heavy chain
constant domain. Here we report the ligand binding proper-
ties of this protein, and compare them to the properties of
bovine cells.
2. Materials and methods
2.1. Interferons
IFNs are designated by their preferred nomenclature [29], with
original or laboratory nomenclature in parentheses. IFN-K2 (= IFN-
KA), IFN-K8 (= IFN-KB2), and IFN-K1 (= IFN-KD) were provided
by Dr. Sidney Pestka (this department). IFN-g was the gift of Dr.
G.R. Adolf (Bender Wien, Vienna, Austria). IFN-L derived from
CHO cells was from Dr. Leona Ling (Biogen Corp., Cambridge,
MA). For calculations, the suppliers’ determination of protein con-
centration was used. Several IFN dilutions from competitive binding
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experiments were assayed for antiviral activity on MDBK cells with
vesicular stomatitis virus (VSV) [30] or on human HeLa-229 cells with
VSV. (Note: The relatively low antiviral activity of IFN-L on MDBK
cells reported here has been noted previously, but the apparent anti-
viral activity can be increased about 10-fold by increasing the length
of the initial incubation between cells and IFN-L from 4 h to 16 h;
J.A.L., unpublished data.)
2.2. BoIFNAR-1/Fc fusion protein
A recombinant fusion protein (‘immunoadhesin’) of the extracellu-
lar domain of BoIFNAR-1 with a human constant heavy immuno-
globulin domain was expressed in Cos7 cells and puri¢ed by a⁄nity
chromatography over Protein A-Sepharose 4B (Pharmacia), as de-
scribed previously for the HuIFNAR-1/Fc fusion [31]. It is referred
to as ‘BoIFNAR-1/Fc’.
2.3. Phosphorylation of interferon
A HuIFN-K2 analogue possessing a phosphorylation site, originally
designated IFN-KA-P1, was phosphorylated to high radiospeci¢c ac-
tivity with [Q-32P]ATP and bovine heart cAMP-dependent protein kin-
ase [32]. Human [32P]IFN-KA-P1 is referred to here as [32P]IFN-K2.
2.4. Solid phase radioligand assay
The protocol was modi¢ed from an ELISA protocol of Mohammad
R. Zafari (Biogen, Inc.; see also [16]). Immulon 2 plates (Dynatech
Laboratories) were coated with 50 Wl of 5 Wg/ml A⁄niPure Goat Anti-
Human IgG FcQ fragment (Jackson ImmunoResearch) in PBS. After
1^2 h the wells were blocked with BSA (5 mg/ml) in PBS for at least
2 h. Wells were washed once with PBS containing 0.05% Tween 20
and twice with PBS. The recombinant BoIFNAR-1/Fc fusion protein
was added (50 Wl/well) at 1.25 Wg/ml in PBS and incubated for v 1 h
at room temperature. Plates were then washed as above. For compe-
tition binding assays, 25 Wl of speci¢c dilutions of non-radioactive
IFNs diluted in 5 mg/ml BSA/PBS (or DMEM with 5% iron-supple-
mented calf serum) was added, followed immediately by 25 Wl of
[32P]IFN-K2 (V0.75^1U105 cpm). After 1 h at room temperature,
plates were placed on ice, and were washed as above (but with ice-
cold solutions) to remove unbound [32P]IFN-K2. Bound [32P]IFN-K2
was eluted with 1% SDS at 55‡ for 10 min, and added to scintillation
£uid for determination of radioactivity. Competition curves were an-
alyzed by non-linear regression to one- or two-site competition mod-
els, using the program Prism v.2.01 (GraphPad Software, Inc., San
Diego, CA).
2.5. Saturation binding and competition curves
Saturation binding assays to cells were done as described [16,28,33].
Brie£y, MDBK cells were trypsinized, collected in medium, and re-
suspended at 0.5^1.0U107 cells/ml. Half of the cells were treated with
v 100-fold excess non-radioactive IFN-K2 (1^3 Wg/ml). Aliquots of
cells with and without excess non-radioactive IFN were then com-
bined with serial dilutions of [32P]IFN-K2, and incubated while rock-
ing for 1 h at room temperature. Cell-bound [32P]IFN-K2 was sepa-
rated from unbound by brief centrifugation through a cushion of 10%
(w/v) sucrose in PBS. Tubes were frozen, cut, and counted to deter-
mine bound and free radioactivity. For competition binding assays,
cells were prepared as for saturation binding, except that cells were
resuspended to 2U concentration (usually 1^2U107 cells/ml). In 96-
well plates, cells were combined with speci¢c dilutions (generally 4-
fold serial dilutions) of di¡erent cold IFNs in addition to [32P]IFN-K2.
Cells were incubated and analyzed as above. For most competition
assays, binding at each concentration of non-radioactive competitor
was measured in triplicate or quadruplicate. Points more than 2 stand-
ard deviations from the mean were omitted from the analysis. Sup-
pliers’ determinations of IFN concentration (in mg/ml) were used for
all calculations.
Data were analyzed by non-linear regression to one- or two-site
binding or competition models, using the program Prism v.2.01
(GraphPad Software, Inc., San Diego, CA). For binding curves, spe-
ci¢c binding is de¢ned as total binding minus non-speci¢c binding.
Competition curves were analyzed in two ways: (1) without any con-
straints; and (2) with the constraint that all curves in a single experi-
ment have the same total binding in the absence of competitive ligand,
and the same non-speci¢c binding in the presence of saturating
amounts of any competitor. Since the constraints are biochemically
reasonable, reported IC50 values and ¢gures are for constrained ¢ts,
unless indicated.
2.6. Crosslinking of labeled IFN to BoIFNAR-1/Fc
Crosslinking of [32P]IFN-K2 to BoIFNAR-1/Fc was initiated by
incubating [32P]IFN-K2 (15 Wl containing V120 000 cpmW1.5U1038
M ¢nal concentration) with BoIFNAR-1/Fc (5 Wl of 0.2 mg/ml) for 3 h
at 4‡C. Parallel control reactions contained, in addition, 10 Wg/ml of
non-radioactive IFN-K2 or 0.1% SDS. After incubation, samples were
reacted with the bifunctional crosslinking reagent BS3 (0.5 mM ¢nal
concentration; Pierce Chemical Co.) for 20 min at 4‡C [17]. Cross-
linked products were analyzed by SDS-polyacrylamide gel electropho-
resis (PAGE) on a 10% acrylamide gel [34], with BioRad Kaleido-
scope molecular weight standards.
3. Results
The BoIFNAR-1/Fc protein was expressed transiently in
COS cells and puri¢ed by a⁄nity chromatography on Protein
A-Sepharose 4B. When analyzed by SDS-PAGE under reduc-
ing conditions, it migrates with a Mr of V118 000, compared
with a mass of 62 019 calculated from the polypeptide se-
quence (assuming a mature amino terminus of Ser-Gly-Glu;
data not shown). This substantial size di¡erence presumably
re£ects post-translational modi¢cations, particularly N-linked
glycosylation. In the absence of reducing agents, BoIFNAR-1/
Fc migrates with a Mr of s 200 kDa. This is consistent with
the native form being a disul¢de-linked dimer, probably
through the immunoglobulin heavy chain, as often seen with
other immunoadhesins.
In solution, the BoIFNAR-1/Fc protein binds [32P]IFN-K2
to which it can be covalently crosslinked in a high molecular
weight complex (Fig. 1, lane 1). The size of the covalent com-
plex suggests that it consists of a BoIFNAR-1/Fc dimer and
one or two molecules of [32P]IFN-K2. This complex is not
formed when excess non-radioactive IFN-K2 is present, nor
when the proteins are denatured by 0.1% SDS (lanes 2, 3).
As expected for an e⁄cient IFN binding protein, BoIF-
NAR-1/Fc can compete in solution for the high-a⁄nity bind-
ing of [32P]IFN-K2 to human Daudi cell (Fig. 2). The IC50 for
BoIFNAR-1/Fc was 1.3^1.7 nM under these conditions. Us-
ing an approximate value of 1U10310 M for the Kd of
[32P]IFN-K2 on Daudi cells, the calculated Ki for BoIF-
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Fig. 1. Covalent complex of [32P]IFN-K2 and BoIFNAR-1/Fc.
BoIFNAR-1/Fc was incubated with [32P]IFN-K2 in the absence
(lane 1) or presence (lane 2) of 10 Wg/ml nonradioactive IFN-K2, or
under denaturing conditions (0.1% SDS; lane 3). Samples were co-
valently crosslinked with BS3 reagent (Pierce Chemical Co.), ana-
lyzed on a 10% acrylamide gel, and autoradiographed. Mr values
were determined relative to prestained protein standards (GIBCO)
and ‘Kaleidoscope’ prestained markers (Biorad).
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NAR-1/Fc is 1.4U10310 M, demonstrating high a⁄nity. This
competition is as e⁄cient or more so than several well char-
acterized neutralizing monoclonal antibodies (LI-1, LI-8; [35])
directed against the ligand IFN-K2 (data not shown).
A convenient radioligand binding assay (RLA) was devel-
oped with BoIFNAR-1/Fc immobilized non-covalently on a
microtiter plate through goat anti-human IgG adsorbed to the
plate. In this format, [32P]IFN-K2 was e⁄ciently bound to the
immunoadhesin (Fig. 3), with very low non-speci¢c binding.
From these data, an a⁄nity of BoIFNAR-1/Fc for IFN-K2
was estimated at about 10 nM. However, the high amount of
BoIFNAR-1/Fc bound to the plates, with an attendant high
capacity for IFN binding, makes this an upper estimate for
the true a⁄nity, which is likely to be closer to the Ki of 0.14
nM.
The RLA provides a convenient format to explore the li-
gand speci¢city of BoIFNAR-1. Diverse non-radioactive type
I IFNs were tested for their ability to compete with [32P]IFN-
K2 for binding to BoIFNAR-1/Fc. All human ligands tested ^
IFN-K2, IFN-K1, IFN-K8, IFN-L, and IFN-g ^ competed for
binding, with IC50 values ranging from 7U10310 to 8U1038
M (Fig. 4A,B; Table 1). The a⁄nity of the ligands varied in
the order: IFN-K2WIFN-K1s IFN-gs IFN-K8s IFN-L.
The same ligands were tested for their ability to compete
with [32P]IFN-K2 for binding to bovine MDBK cells, and
for their antiviral activity on MDBK cells (Table 1).
For comparison, and as an internal control for the integrity
and activity of the interferons, binding and antiviral activities
are also presented for human Daudi cells and HeLa cells,
respectively (Table 1). On human cells, the human IFNs dis-
play their typical activities and a⁄nities in the general order
IFN-K8s IFN-K2, IFN-g and IFN-L. IFN-K1 showed con-
siderably lower biological activity and receptor a⁄nity, as
consistently reported.
4. Discussion
Because of the serendipitous ¢nding of broad speci¢city and
high a⁄nity of bovine cells for human type I IFN-Ks, the
bovine homologue of IFNAR-1 was cloned and characterized
[17,27,28]. The ectopic expression of BoIFNAR-1 in mouse
and human cells, which have endogenous type I IFN recep-
tors, conferred on these cells a speci¢city similar to that of
bovine cells [27,28]. With COS cells expressing BoIFNAR-1 at
levels about 100-fold above the endogenous type I receptor, or
with Xenopus oocytes, which show no evidence of an interfer-
on system, BoIFNAR-1 confers high a⁄nity binding of
HuIFN-K2 and IFN-K8 [17,28]. This contrasts starkly with
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Fig. 4. Competition of type I IFNs for [32P]IFN-K2 binding to BoIFNAR-1/Fc. A: Representative data. B: Compilation of IC50 values from
independent competition experiments for each ligand. Each point represents an independent determination of the IC50. Horizontal lines repre-
sent the average of the values.
Fig. 3. Binding of [32P]IFN-K2 by immobilized BoIFNAR-1/Fc. In-
creasing amounts of [32P]IFN-K2 were added in the absence and
presence of 2 Wg/ml non-radioactive IFN-K2. The solid line is a
non-linear regression ¢t to the calculated speci¢c binding, with a
one-site binding model. (a) Total binding; (E) non-speci¢c binding;
(b) speci¢c binding.
Fig. 2. Inhibition of [32P]IFN-K2 binding to Daudi cells by BoIF-
NAR-1/Fc. Daudi cells were incubated with the indicated concentra-
tions of BoIFNAR-1/Fc (assuming a mass of 1.2U105 for the cova-
lent dimer) for 15 min at room temperature. [32P]IFN-K2 was added
(about 7U104 cpm; ca. 6.2U10310 M) and incubated at room tem-
perature for 1 h.
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the weak binding of type I IFNs by HuIFNAR-1 [2,16^19],
and the ability of HuIFNAR-1 to confer on murine cells sig-
ni¢cant response to HuIFN-K8, but not other human type I
IFNs [2]. Indeed, binding experiments with a human IFNAR-
1/Fc construct analogous to that described here for BoIF-
NAR-1 failed to detect signi¢cant binding of 32P-labeled
IFN-K2 or IFN-K8 (J.A.L. and L.E.L., unpublished data).
Thus, BoIFNAR-1 plays a major role in di¡erential binding
of human IFNs on bovine cells, whereas, on human cells,
HuIFNAR-2 plays the dominant role in di¡erential ligand
binding.
Here we have demonstrated that a soluble form of the ex-
tracellular domain of BoIFNAR-1 binds [32P]IFN-K2 with
high a⁄nity (0.1^1 nM), and has a very broad speci¢city for
human type I IFNs, including diverse IFN-Ks, IFN-L and
IFN-g. A comparison of the binding activity of human type
I ligands for BoIFNAR-1 with ligand speci¢city data toward
the native receptor on bovine cells is instructive (Table 1);
because of the di¡erent assay conditions for binding to
MDBK cells and to immobilized BoIFNAR-1/Fc, the ratio
of IC50 values for each substrate is more informative than
their absolute values. In competition with [32P]IFN-K2 for
binding to bovine MDBK cells, four of the ligands (IFN-
K2, IFN-K8, IFN-K1, and IFN-g) demonstrate similar high
a⁄nity to that seen with BoIFNAR-1/Fc, while IFN-L has an
a⁄nity almost 100-fold lower. These results roughly correlate
with the antiviral activity on these cells, which is high for the
high-a⁄nity ligands and much lower for IFN-L. For the lig-
ands IFN-K2, IFN-K1, IFN-L, the inhibition constants are 7^
10-fold higher for the BoIFNAR-1/Fc protein than for
MDBK cells. In contrast, the IC50 values for IFN-K8 and
for IFN-g on the BoIFNAR-1/Fc protein are, respectively,
100 and 49 times higher than the IC50 values on MDBK.
These enhanced di¡erences for IFN-K8 and IFN-g between
MDBK cells and the soluble BoIFNAR-1/Fc protein suggest
a stronger dependence on another cellular component (BoIF-
NAR-2?) to approximate the ligand speci¢city of bovine cells.
Expression in heterologous cells of BoIFNAR-1 and BoIF-
NAR-2, singly and together, will permit further dissection of
the relative contributions to the ligand speci¢city, comple-
menting our previous studies of the contributions of human
IFNAR-1 and HuIFNAR-2 to ligand speci¢city [16]. The
comparison of the ligand speci¢city of human IFNs toward
bovine components and human receptor components may al-
low us to determine, in principle, whether the proper function-
ing of a two-component receptor requires one high-a⁄nity
and one low-a⁄nity component, as seen with the native hu-
man type I IFN receptor (HuIFNAR) and with many other
cytokine receptors, or whether the system can operate e⁄-
ciently with two moderate-to-high a⁄nity receptor chains.
The ability of BoIFNAR-1/Fc to bind a wide array of hu-
man type I IFNs contrasts strongly with the weak binding of
these same ligands to HuIFNAR-1. We are exploiting the
di¡erential ligand binding by human and bovine IFNAR-1
to map the ligand binding site on IFNAR-1 (L.A. Goldman
et al., submitted for publication).
BoIFNAR-1 is a useful alternative to the low-a⁄nity HuIF-
NAR-1 for studying the binary and ternary complexes of
IFNs with IFNAR-1 and IFNAR-2. Moreover, in binding
all the human type I IFNs examined, it has a broader specif-
icity than either the soluble ectodomain of human IFNAR-2
(Table 1), or than various anti-IFN monoclonal antibodies.
BoIFNAR-1 may thus provide a broad-spectrum reagent for
the assay, puri¢cation, and inhibition of human type I IFNs.
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